Skip to content

Author

S. Ryhänen

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Immunotherapy refractoriness and early post-alloHCT relapse define ultra-high-risk B-ALL after CD19 CAR T-cell therapy.

CD19-directed CAR T-cell therapy (CART19) has transformed relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) management, but the prognostic impact of immunotherapy sensitivity and post-allogeneic hematopoietic cell transplantation (alloHCT) relapse timing in real-world practice remains unclear. We re...

V. Ortíz-Maldonado, J. Galimard, Giorgio Ottaviano et al. · 0 citations
Case report Open access Sep 2026

Neurofibromatosis 1 (NF1) gene testing reveals rising variant allele fraction as an early warning sign of juvenile myelomonocytic leukemia.

Molecular analysis of the NF1 gene is part of the diagnostic criteria for neurofibromatosis type 1 (NF1) and is particularly useful in young children who do not yet exhibit sufficient clinical signs for diagnosis. Juvenile myelomonocytic leukemia (JMML) is a rare pediatric myelodysplastic/myeloproliferative neoplasm th...

S. Peltonen, Christian Johansson, Marika H. Grönroos et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.